Preference-based quality-of-life in patients with Parkinson's disease

被引:67
作者
Siderowf, A
Ravina, B
Glick, HA
机构
[1] Univ Penn, Sch Med, Dept Neurol, Div Gen Internal Med, Philadelphia, PA 19107 USA
[2] Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19107 USA
关键词
D O I
10.1212/WNL.59.1.103
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Preference-based instruments are a specific type of health-related quality-of-life scale designed to measure the relative value of health. Because of this property, they are the appropriate measures of quality of life for cost-effectiveness analysis. Although preference-based scales are widely used, their validity has rarely been tested in specific patient groups. Objectives: To assess quality of life using preference-based scales in a group of patients with PD and to compare these scores with measures of clinical severity and traditional quality of life. Methods: Each patient was rated using the Disability and Distress Index (DDI), the Euroqol System (EQ-5D), and the Health Utilities Index Mark II (HUI). Clinical severity was measured using the Unified PD Rating Scale (UPDRS) and PD Questionnaire-39 (PDQ-39) quality-of-life instrument. Results from preference-based instruments were compared with each other and with clinical measures of disease severity. Results: One hundred subjects participated in the study, and 97 completed all preference-based instruments. Scores from all three instruments correlated well with the UPDRS and most domains of the PDQ-39. The mean scores for the DDI, HUI, and EQ-5D were 0.92 (range 0 to 1), 0.74 (range 0.19 to 1), and 0.58 (range -0.429 to 1). Differences between mean scores for the instruments were significant. Conclusions: In the sample of patients with PD, the Disability and Distress Index, Euroqol System, and the Health Utilities Index Mark II correlate well with measures of disease severity and quality of life. However, they give strikingly different values. When applied in cost-effectiveness analysis, these discrepancies could result in substantially different cost-effectiveness ratios for PD-related interventions.
引用
收藏
页码:103 / 108
页数:6
相关论文
共 20 条
[1]   AN INVENTORY FOR MEASURING DEPRESSION [J].
BECK, AT ;
ERBAUGH, J ;
WARD, CH ;
MOCK, J ;
MENDELSOHN, M .
ARCHIVES OF GENERAL PSYCHIATRY, 1961, 4 (06) :561-&
[2]   Deriving a preference-based single index from the UK SF-36 Health Survey [J].
Brazier, J ;
Usherwood, T ;
Harper, R ;
Thomas, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1115-1128
[3]   Applicability of the health utilities index to a population of childhood survivors of central nervous system tumours in the UK [J].
Glaser, AW ;
Furlong, W ;
Walker, DA ;
Fielding, K ;
Davies, K ;
Feeny, DH ;
Barr, RD .
EUROPEAN JOURNAL OF CANCER, 1999, 35 (02) :256-261
[4]   PARKINSONISM - ONSET PROGRESSION AND MORTALITY [J].
HOEHN, MM ;
YAHR, MD .
NEUROLOGY, 1967, 17 (05) :427-&
[5]  
KAPLAN RM, 1988, HEALTH SERV RES, V23, P203
[6]   Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial [J].
Kurth, MC ;
Adler, CH ;
StHilaire, M ;
Singer, C ;
Waters, C ;
LeWitt, P ;
Chernik, DA ;
Dorflinger, EE ;
Yoo, K ;
Lieberman, AN ;
Brewer, M ;
SaintHilaire, M ;
Pery, LM ;
Thomas, C ;
Turpin, L ;
OBrien, CF ;
Seeberger, LC ;
Duncan, KL ;
Caviness, JN ;
Douglas, M ;
Wheeler, K ;
Riley, D ;
Rainey, P ;
Tanner, CM ;
Kelker, K ;
Lewis, P ;
Trosch, RM ;
Mistura, KL ;
Montgomery, EB ;
Lindsey, B ;
Weiner, W ;
Shulman, LM ;
Sheldon, C ;
Waters, CH ;
Welsh, M ;
Trugman, JM ;
Landow, ER ;
Pedder, SCJ ;
Shimon, GS ;
Magni, G .
NEUROLOGY, 1997, 48 (01) :81-87
[7]   THE FREQUENCY OF IDIOPATHIC PARKINSONS-DISEASE BY AGE, ETHNIC-GROUP, AND SEX IN NORTHERN MANHATTAN, 1988-1993 [J].
MAYEUX, R ;
MARDER, K ;
COTE, LJ ;
DENARO, J ;
HEMENEGILDO, N ;
MEJIA, H ;
TANG, MX ;
LANTIGUA, R ;
WILDER, D ;
GURLAND, B ;
HAUSER, A .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (08) :820-827
[8]  
Parkinson Study Group, 2000, JAMA, V284, P1931
[9]  
PEAR R, 2002, NY TIMES 0108, pA14
[10]  
PECHEVIS M, 2001, PARKINSONISM REL D S, V7, pS106